PHARMACOKINETICS OF VM-26 GIVEN INTRAPERICARDIALLY OR INTRAVENOUSLY IN PATIENTS WITH MALIGNANT PERICARDIAL-EFFUSION

被引：16

作者：

FIGOLI, F

ZANETTE, ML

TIRELLI, U

SORIO, R

LESTUZZI, C

URSO, R

MONFARDINI, S

DINCALCI, M

机构：

[1] MARIO NEGRI INST PHARMACOL RES,I-20157 MILAN,ITALY

[2] CTR RIFERIMENTO ONCOL,AVIANO,ITALY

[3] OSPED CIVILE,PORDENONE,ITALY

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 1987年 / 20卷 / 03期

关键词：

D O I：

10.1007/BF00570493

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：239 / 242

页数：4

共 25 条

[1]

ALLEN LM, 1982, CANCER CHEMOTH PHARM, V7, P151

[2] TENIPOSIDE (VM-26), AN OVERLOOKED HIGHLY-ACTIVE AGENT IN SMALL-CELL LUNG-CANCER - RESULTS OF A PHASE-II TRIAL IN UNTREATED PATIENTS [J].

BORK, E ;

HANSEN, M ;

DOMBERNOWSKY, P ;

HANSEN, SW ;

PEDERSEN, AG ;

HANSEN, HH .

JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (04) :524-527

[3]

CASPER ES, 1983, CANCER TREAT REP, V67, P235

[4] COMPARISON BETWEEN VP-16 AND VM-26 IN LEWIS LUNG-CARCINOMA OF THE MOUSE [J].

COLOMBO, T ;

BROGGINI, M ;

VAGHI, M ;

AMATO, G ;

ERBA, E ;

DINCALCI, M .

EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1986, 22 (02) :173-179

[5] INTRA-PERICARDIAL TETRACYCLINE FOR MANAGEMENT OF CARDIAC-TAMPONADE SECONDARY TO MALIGNANT PERICARDIAL-EFFUSION [J].

DAVIS, S ;

SHARMA, SM ;

BLUMBERG, ED ;

KIM, CS .

NEW ENGLAND JOURNAL OF MEDICINE, 1978, 299 (20) :1113-1114

[6]

DINCALCI M, 1982, CANCER TREAT REP, V66, P231

[7]

DINCALCI M, 1985, CANCER TREAT REP, V69, P73

[8] INVITRO CYTO-TOXICITY OF VP-16 ON PRIMARY TUMOR AND METASTASIS OF LEWIS LUNG-CARCINOMA [J].

DINCALCI, M ;

ERBA, E ;

VAGHI, M ;

MORASCA, L .

EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1982, 18 (04) :377-380

[9]

DONELLI MG, 1984, CANCER TREAT REP, V68, P381

[10]

EVANS WE, 1982, CANCER CHEMOTH PHARM, V7, P147

← 1 2 3 →